^
BIOMARKER:

DDR

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
DDR
Ovarian Cancer
BAY 1895344
Sensitive
:
C3
IGCS 2022 - 2 weeks - (New C3)
DDR
Prostate Cancer
durvalumab
Sensitive
:
C2
DDR
Cervical Cancer
BAY 1895344
Sensitive
:
C2
DDR
Non Small Cell Lung Cancer
PD-L1 inhibitor + CTLA4 inhibitor
Sensitive
:
C3
DDR
Non Small Cell Lung Cancer
atezolizumab
Sensitive
:
C3
DDR
Cholangiocarcinoma
lenvatinib + toripalimab
Sensitive
:
C3
DDR
Colorectal Cancer
CAPOX
Sensitive
:
C3
DDR
Colorectal Cancer
FOLFOX
Sensitive
:
C3
DDR
Colorectal Cancer
Immunotherapy
Sensitive
:
C3
DDR
Triple Negative Breast Cancer
pembrolizumab + niraparib
Sensitive
:
C3
DDR
Prostate Cancer
nivolumab + ipilimumab
Sensitive
:
C3
DDR
Prostate Cancer
olaparib
Sensitive
:
C3
DDR
Prostate Cancer
abiraterone acetate + prednisone
Resistant
:
C3
DDR
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive
:
C3
DDR
Non Small Cell Lung Cancer
ABT-888
Sensitive
:
C3
DDR
Renal Cell Carcinoma
Tyrosine kinase inhibitor
Sensitive
:
C3
DDR
Breast Cancer
Immunotherapy
Sensitive
:
C3
DDR
Bladder Cancer
Immunotherapy
Sensitive
:
C3
DDR
Melanoma
Immunotherapy
Sensitive
:
C3
DDR
Prostate Cancer
talazoparib
Sensitive
:
C3
DDR
Pancreatic Cancer
olaparib
Sensitive
:
C3
DDR
Hepatocellular Cancer
FOLFOX
Sensitive
:
C3
DDR
Soft Tissue Sarcoma
olaparib
Sensitive
:
C3
DDR
Solid Tumor
niraparib
Sensitive
:
C3
DDR
Clear Cell Renal Cell Carcinoma
VEGFR inhibitor
Sensitive
:
C3